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THE LONG-TERM results of transplantation against a true positive historic crossmatch due to IgG alloanti-
body are unclear. Tacrolimus is a novel immunosuppressive 
agent that has been found to be safe and effective in renal 
transplantation. l We report herein our long-term experi-
ence with 47 patients (mean age 41.8 :!: 14.3 years) who 
underwent cadaveric renal transplantation against a posi-
tive historic-current negative T-cell crossmatch under ta-
crolimus immunosuppression. There were 24 (51%) pri-
mary and 23 (49%) retransplants. In 18 patients the 
cross match remained positive with dithiothreitol (DIT), 
including 10 (44%) of the retransplants and eight (35%) of 
the primary recipients. With a median follow-up of 45.2 
months, the overall patient and graft survival rates are 
89.4% and 64%, and the 2-year actuarial survival rates are 
89.4% and 74.5%. The overall graft survival rates were 
similar (P = NS) for the DIT-positive and DIT-negative 
patients (66.7% versus 62.1%) and primary and retrans-
plant recipients (62.5% versus 65.2%). Of the nine patients 
who lost their previous graft to rejection, six currently have 
a functioning graft. Twenty-seven (57%) patients had at 
0041-1315/97/$17.00 
PI! S0041-1345(96)000278-3 
312 
least one episode ofrejection and 11 (41%) required OKT3 
for steroid-resistant rejection. Despite this, complete ste-
roid withdrawal has been possible in 63% of the 30 patients 
with a functioning graft. Unlike previous reports, we ob-
served satisfactory long-term results in both primary and 
retransplanted recipients, including those with previous 
accelerated graft loss, whether the crossmatch was due to 
IgG or IgM. Tacrolimus may be an agent particularly suited 
for use in this group at high immunologic risk. 
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